Abstracts tagged "Economics"

Abstract Number: 1759 • 2017 ACR/ARHP Annual Meeting
Economic Evaluation of Rituximab Versus Azathioprine for Maintenance Treatment of ANCA-Associated Vasculitis. a Prospective, Multicenter Study
Annalisa Montante¹, Alicia Le Bras², Benjamin Terrier³, Pascal Cohen³, Xavier Puéchal⁴, Alexandre Karras⁵, Philippe Ravaud⁶, Loïc Guillevin⁷ and Isabelle Durand-Zaleski⁸, ¹UNITÉ DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, ²UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, ³Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁴Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ⁵Nephrology, HEGP, Paris, France, ⁶Hôpital Hôtel Dieu, Paris, France, ⁷Internal medicine, Cochin University Hospital, paris, France, ⁸UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE DE PARIS-CRETEIL, PARIS, France
Background/Purpose: Rituximab was proven to be superior to azathioprine as maintenance therapy for ANCA-associated vasculitides (AAVs) at month 28 of MAINRITSAN-1–trial follow-up. Because of rituximab’s…
Abstract Number: 2251 • 2017 ACR/ARHP Annual Meeting
Preferences for Physical Activity: A Discrete Choice Experiment in People with Chronic Knee Pain
Daniel Pinto¹, Ulf Bockenholt², Rowland W. Chang^3,4, Julia (Jungwha) Lee⁵, Jane Holl⁶, Daniel Finn⁶, Leena Sharma⁷, Allen Heinemann⁸ and Paul Hansen⁹, ¹Department of Physical Therapy & Human Movement Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Department of Marketing, Kellogg School of Management, Northwestern University, Evanston, IL, ³Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Preventive Medicine, Medicine, and Physical Medicine & Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Center for Healthcare Studies, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Center for Rehabilitation Outcomes Research, Shirley Ryan Ability Lab, Chicago, IL, ⁹Economics, University of Otago, Dundin, New Zealand
Preferences For Physical Activity: A Discrete Choice Experiment In People With Chronic Knee Pain Background/Purpose: Understanding preferences for physical activity (PA) can help guide patient…
Abstract Number: 2497 • 2017 ACR/ARHP Annual Meeting
The Role of Individual and Country-Level Socio-Economic Factors in Work Participation in Patients with Spondyloarthritis across 22 Countries Worldwide: Results from the Comospa Study
Santiago Rodrigues Manica^1,2, Alexandre Sepriano^3,4, Sofia Ramiro^5,6, Fernando Pimentel-Santos^1,2, Polina Putrik⁷, Elena Nikiphorou^8,9, Anna Moltó^10,11, Maxime Dougados^11,12, Désirée van der Heijde¹³, Robert B.M. Landewé¹⁴, Filip van Den Bosch¹⁵ and Annelies Boonen⁷, ¹CEDOC, NOVA Medical School, Lisbon, Portugal, ²Rheumatology, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal, ³CEDOC, NOVA Medical School, Lisboa, Portugal, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁶R. Câmara Pestana 6, CEDOC, NOVA Medical School, Lisbon, Portugal, ⁷MUMC+, Maastricht, Maastricht, Netherlands, ⁸Whittington Hospital, London, United Kingdom, ⁹Academic Rheumatology Department, King's College London, London, United Kingdom, ¹⁰Rheumatology B Department, Paris Descartes University, Cochin Hospital, AP-HP,Paris, Paris, France, ¹¹7 INSERM (U1153), Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France, ¹²Paris, Paris, France, ¹³Leiden University Medical Center, Leiden, Netherlands, ¹⁴Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ¹⁵Rheumatology, Ghent University Hospital, Gent, Belgium
Background/Purpose: Spondyloarthritis (SpA) carries substantial financial costs, including direct costs (use of medical services and treatments) and indirect costs (loss of work productivity). While disease…
Abstract Number: 133 • 2017 ACR/ARHP Annual Meeting
Impact of the Five Components of the Euroqol 5-Dimensions Instrument on Healthcare and Work-Loss Costs in Rheumatoid Arthritis: Observational Data from Southern Sweden
Anders Gülfe¹, Tor Olofsson¹, Jonas K Söderling², Martin Neovius² and Johan K Wallman¹, ¹Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ²Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Healthcare and work-loss costs are markedly higher in RA patients than in the general population. The EuroQol 5-Dimensions (EQ-5D) instrument, commonly applied to measure…
Abstract Number: 199 • 2017 ACR/ARHP Annual Meeting
Incremental Direct Medical Costs of Systemic Lupus Erythematosus Patients in the Years Preceding Diagnosis and the Impact of Sex: A General Population-Based Study
Natalie McCormick^1,2, Carlo Marra³ and J. Antonio Avina-Zubieta⁴, ¹Arthritis Research Canada, Richmond, BC, Canada, ²Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada, ³School of Pharmacy, University of Otago, Dunedin, New Zealand, ⁴Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Little is known about the healthcare costs of systemic lupus erythematosus (SLE) patients in the years leading up to SLE diagnosis. We estimated the…
Abstract Number: 224 • 2017 ACR/ARHP Annual Meeting
Patterns of Methotrexate Use in African Countries with Low Versus Medium/High Human Development Index: Preliminary Results of Semi-Structured Interviews
Carol A Hitchon¹, Yan Liu², Steven Shi³, Girish M Mody⁴, Candace H. Feldman⁵, Michael Weinblatt⁶ and Ines Colmegna⁷, ¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, ²McGill University, Montreal, QC, Canada, ³University de Montreal, Montreal, QC, Canada, ⁴Dept of Rheumatology, University of Kwa Zulu-Natal, Durban, South Africa, ⁵Brigham and Women’s Hospital, Division of Rheumatology, Immunology and Allergy, Boston, MA, ⁶Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Division of Rheumatology, Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada
Background/Purpose: Methotrexate (MTX) is standard therapy for rheumatoid arthritis (RA) and also used to treat other rheumatic diseases. Existing guidelines for RA treatment/ MTX use…
Abstract Number: 414 • 2017 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity and Autoantibody Status Lead to Cost Effective Tapering Algorithms in Rheumatoid Arthritis Patients in Sustained Remission
Melanie Hagen¹, Matthias Englbrecht², Judith Haschka³, Michaela Reiser⁴, Arnd Kleyer⁵, Axel J. Hueber⁶, Bernhard Manger⁷, Camille Figueiredo⁸, Jayme Fogagnolo Cobra⁹, Hans-Peter Tony¹⁰, Stefanie Finzel¹¹, Stefan Kleinert¹², Joerg Wendler¹³, Florian Schuch¹³, Monika Ronneberger¹³, Martin Feuchtenberger¹⁴, Martin Fleck^15,16, Karin Manger¹⁷, Matthias Schmitt-Haendle¹⁸, H.-M. Lorenz¹⁹, HG Nüßlein²⁰, Rieke Alten²¹, Joerg C. Henes²², Klaus Krüger²³, Georg Schett² and Juergen Rech²⁴, ¹University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ³Medical Department II, St. Vincent Hospital, the VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁴Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Dept of Medicine 3, Rheumatology and Clinical Immunology, Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, ⁶Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁷Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Institution de Rheumatologia, Sao Paolo, Brazil, ⁹Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, ¹⁰Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ¹¹University of Freiburg, Freiburg, Germany, ¹²Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, ¹³Schwerpunktpraxis Rheumatologie, Erlangen, Germany, ¹⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ¹⁵Department of Rheumatology and Clinical Immunology, Asklepios Medical Center Bad Abbach, Bad Abbach, Germany, ¹⁶Internal Medicine I, University Medical Center of Regensburg, Regensburg, Germany, ¹⁷Rheumatology Practice Bamberg, Bamberg, Germany, ¹⁸Rheumatology Practice, Bayreuth, Germany, Bayreuth, Germany, ¹⁹Rheumatology, University Heidelberg, Heidelberg, Germany, ²⁰Rheumatology Practice Nuremberg, Nuremberg, Germany, ²¹Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ²²Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ²³Praxiszentrum St.Bonifatius, Munich, Germany, ²⁴Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany
Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…
Abstract Number: 113 • 2016 ACR/ARHP Annual Meeting
Online Consultation for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tools: A Study of Medical Economics
Fei Xiao¹, Xiangyuan Liu², Zhijun Li³, Tong Xie⁴, Xinwang Duan⁵, Huiqiong Zhou⁶, Yanhong Huang⁷, Yi Zheng⁸, Hua Wei⁹, Hongzhi Wang¹⁰, Rong Mu¹¹, Hui Xiao¹, Yuhua Jia¹, Yonggang Zhao¹, Yuan Liu¹ and Fengchun Zhang¹², ¹Gothic Internet Technology Corporation, Shanghai, China, ²Department of Rheumatology and Immunology, Peking University Third hospital, Bei jing, China, ³The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ⁴Affiliated hospital of Guangdong medical University, Zhanjiang, China, ⁵Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁶The First Affiliated Hospital of PLA General Hospital, Beijing, China, ⁷Beijing Jishuitan Hospital, Beijing, China, ⁸8 Gongren Tiyuchang Nanlu, Cha, Beijing Chao-Yang Hospital, Beijing, China, ⁹No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ¹⁰The First Hospital of Jiaxing, Jiaxing, China, ¹¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ¹²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background/Purpose: China does not have primary medical care and referral system. Patients can choose any hospital or any doctor they like to seek medical care.…
Abstract Number: 228 • 2016 ACR/ARHP Annual Meeting
Sick Leave and Disability Pension in Working-Age Gout Patients before and after Diagnosis – a Population Based Case-Control Study
Valgerdur R Sigurdardottir¹, Lennart TH Jacobsson², Panagiota Drivelegka², Anna Svärd^1,3 and Mats Dehlin², ¹Rheumatology Clinic, Falun Hospital, SE-791 82 Falun, Sweden, Falun, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Center for Clinical Research Dalarna, Falun, Sweden
Background/Purpose: Gout is the most common form of inflammatory arthritis with a prevalence of 1.5% in our area in the age group 50-59 years. Gout…
Abstract Number: 1237 • 2016 ACR/ARHP Annual Meeting
The Economic Burden of Dermatomyositis and Polymyositis in the US
J. Bradford Rice¹, Alan White¹, Philip Galebach¹, Andrea Lopez¹, Patricia Schepman², Breanna Popelar³, Michael Philbin⁴ and Elaine Boing², ¹Analysis Group, Inc., Boston, MA, ²Affiliated with Mallinckrodt Pharmaceuticals at the time this study was conducted, Hazelwood, MO, ³Xcenda, L.L.C., Palm Harbor, FL, ⁴Mallinckrodt Pharmaceuticals, Hazelwood, MO
Background/Purpose: Dermatomyositis and polymyositis (DM/PM) are inflammatory myopathies that can lead to persistent muscle weakness and disability. Although significant healthcare resource utilization (HCRU) and work…
Abstract Number: 1243 • 2016 ACR/ARHP Annual Meeting
Validity of the Short Form 6D Utility Measure in Early Axial Spondyloarthritis
Cécile Gaujoux-Viala¹, Laure Gossec², Christel Castelli³, Cédric Lukas⁴, Françoise Barchechath-Flaisler⁵, Jean-Pierre Daures⁶ and Maxime Dougados⁷, ¹Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, ²Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France, ³BESPIM, Nîmes University Hospital and EA2415, Nîmes, France, ⁴Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁵Nîmes University Hospital, Rheumatology Department, Nimes, France, ⁶EA2415, Nîmes, France, ⁷Paris Descartes University, Paris, France
Background/Purpose: The quantification of health improvements is essential, notably in the current context of increasingly expensive therapies and more and more limited resources. Preference-based measures…
Abstract Number: 1607 • 2016 ACR/ARHP Annual Meeting
The Development of a New Anti–Interleukin 6 Blocker for Rheumatoid Arthritis Patients
Alan Glicklich¹, Paul Grayson¹, Christophe Blanchetot², Qing Zhou³ and Anke Kretz-Rommel¹, ¹Bird Rock Bio, Inc, La Jolla, CA, ²Argenx, Ghent, Belgium, ³Genor BioPharma, Shanghai, China
Background/Purpose: While interleukin-6 (IL-6) blockade with monoclonal antibodies is an established, clinically validated mechanism for the treatment of rheumatoid arthritis (RA), the need for significant…
Abstract Number: 2252 • 2016 ACR/ARHP Annual Meeting
Estimated Cost of SLE Hospitalizations
Kayla Neville¹, James Miceli¹, Jianhua Li², Samantha Nguyen³, Teja Kapoor³ and Anca Askanase³, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, ³Medicine, Division of Rheumatology, Columbia University Medical Center, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) treatment comes at a high price, with both direct costs related to healthcare resource utilization and indirect ones related to…
Abstract Number: 1295 • 2015 ACR/ARHP Annual Meeting
Online Consultation for Rheumatic Disease Patients Based on Smart System of Disease Management (SSDM) Mobile Tools: A Study of Medical Economics
Fei Xiao¹, Xiangyuan Liu², Hua Wei³, Zhijun Li⁴, Yanhong Huang⁵, Yaohu Jiang⁶, Huiqiong Zhou⁷, Jie Shen⁸, Yuhua Jia¹, Li Zhang¹, Yuan Liu¹, Minjun Wang¹ and Fengchun Zhang⁹, ¹Gothic Internet Technology Corporation, Shanghai, China, ²Department of Rheumatology and Immunology, Peking University Third hospital, Bei jing, China, ³No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ⁴The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ⁵Beijing Jishuitan Hospital, Beijing, China, ⁶Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China, ⁷The First Affiliated Hospital of PLA General Hospital, Beijing, China, ⁸University of Rochester, Rochester, NY, ⁹Department of Rheumatology, Peking Union Medical college Hosptial, Beijing, China
Background/Purpose: China has no primary medical care and referral system. Patients can choose any hospitals or any doctors they like to seek medical care. As…
Abstract Number: 1678 • 2015 ACR/ARHP Annual Meeting
Does the Level of Disease Control Achieved with Biologics Influence Overall Costs for Health Care and Work Loss in RA?
Jonas K Eriksson¹, Martin Neovius², Johan Askling³ and ARTIS study group, ¹Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Numerous studies have modeled whether biologic drugs are good value for money in the treatment of RA, in terms of reducing health care use…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].